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1860Objectives: The association of new-onset postoperative atrial fibrillation (POAF) and late death after coronary
artery bypass grafting (CABG) has been confounded by the frequent concomitant serious complications that co-
occur with POAF.We aimed to define the magnitude and time dependence of the effect of isolated POAF on late
survival after uncomplicated CABG to comprehensively account for comorbidity and perioperative confounding
factors.
Methods: Nonsalvage CABG patients with no history of AF, no concomitant aortic or valvular surgery, and no
perioperative complications other than POAFwere studied (n¼ 6305). Patients were divided into AF (n¼ 1211,
68 years old, 72%male) and no-AF (n¼ 5094, 63 years old, 70%male) groups. Propensity matching was done
using 55 patient variables, including coronary grafts, completeness of revascularization, and transfusion data.
The AF effect was quantified using time-segmented hazard ratios by Cox regression analysis.
Results: Single (1-to-1), double (1-to-2), and triple (1-to-3) propensity matching of the AF and no-AF was
achieved for 1196, 993, and 719 cases, respectively. The AF group showed significantly worse, yet time-
varying, 0- to 18-year survival: 0 to 1 year, HR, 1.18 (95% confidence interval, 0.77-1.81); 1 to 6 years, HR,
1.37 (95% confidence interval, 1.12 to 1.67); and 6 to 17 years, HR, 1.25 (95% confidence interval, 1.05 to
1.49).
Conclusions: Isolated POAF was associated with a time-varying increase in mortality after CABG. Given these
findings and the high incidence of POAF, efforts to reduce POAF should be pursued to potentially improve
resource usage, morbidity, and mortality. (J Thorac Cardiovasc Surg 2014;148:1860-8)Supplemental material is available online.
New-onset postoperative atrial fibrillation (POAF) is a
frequent complication of cardiac surgery (10%-65%)1-6 and
has been associated with increased morbidity, in-hospital
mortality, and greater resource usage.1-10 Imbalance of the
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The Journal of Thoracic and Cardiovascular Surischemia, and a predisposing anatomic substrate has been
implicated in PAOF; however, the exact pathophysiology
of POAF is poorly understood. The incidence of POAF after
coronary artery bypass grafting (CABG; 15%-40%) has
reportedly been predicted by patient demographics,
including older age, lower ejection fraction, hypertension,
heart failure, prolonged cardiopulmonary bypass, enlarged
left atrium, perioperative medications, and enhanced
inflammatory and oxidative stress.7-10
A number of recent studies have extended the adverse ef-
fects of POAF after CABG to include significantly worse
late mortality.2,9,11-16 If true, this finding is of substantial
clinical importance, given the high incidence of POAF;
however, the specific mechanism by which an ostensibly
limited perioperative arrhythmia, such as POAF, affects
long-term survival is unclear. The available evidence on
this POAF–late mortality association has been limited by
the nonuniformity of the analyses and findings and/or
incomplete accounting for known determinants of late mor-
tality after CABG. No studies, thus far, account for (1)
extent of arterial grafting and (2) completeness of coronary
revascularization.17-22 Furthermore, homologous blood
product transfusion, which has been notably more
frequent in patients with a greater likelihood of POAF and
has been identified as a predictor of late mortality has
also been largely ignored in studies of the effects ofgery c November 2014
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AF group ¼ isolated POAF without other
complications
AF/C group ¼ POAF and other complications
no-AF group ¼ no POAF or any other
postoperative complication
no-AF/C group ¼ no POAF but other complications
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HR ¼ hazard ratio
HRt ¼ time-segmented HR
POAF ¼ postoperative atrial fibrillation
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DPOAF.23-25 In addition, POAF has frequently been
associated with other serious postoperative complications.
Consequently, the interplay between these nonarrhythmic
complications and POAF might have confounded the
independent effects of these conditions on operative and,
possibly, late death.2,8,9,11 Separating the late effects of
POAF and concurrent complications is difficult, and
studies, thus far, have either ignored this13,26 or have
relied on multivariate Cox regression modeling to account
for some, but not all, such complications.2,9,11,14,27
Finally, the potentially time-varying POAF effect on late
mortality, its duration, and the period of greatest risk has
not been described.
Within this construct, we reasoned that if POAF indepen-
dently leads to increased late CABG mortality, it should do
so even (1) in the absence of other nonarrhythmic postoper-
ative complications, and (2) after more comprehensive
adjustment for other known pre-, intra-, and postoperative
predictors of late survival. Accordingly, we investigated
the POAF–late CABG survival association in a manner
that avoids these limitations by more comprehensive
accounting of patient variables, operative and grafting de-
tails, transfusion status, and, most importantly, by excluding
patients with other complications.METHODS
The present investigation was a retrospective analysis of a prospectively
collected data from the Society of Thoracic Surgeons Adult Cardiac Sur-
gery National Database. The Mercy Saint Vincent Medical Center (Toledo,
Ohio; 1994-2007) institutional review board approved our study. Data
collection was performed in compliance with the Society of Thoracic Sur-
geons Database definitions and criteria and did not involve an additional
review of the hospital records or interviewing the patients; thus, the
informed consent requirement was waived.
Patients
Patients undergoing isolated CABG from 1994 to 2007 were included in
the present analysis. CABG patients with concurrent coronary or carotid
reconstruction were also included. Patients were excluded in the case ofThe Journal of Thoracic and Carconcomitant valvular, congenital cardiac or aortic surgery, a documented
history of preoperative atrial fibrillation (AF) or atrial flutter, or emergency
salvage status. A total of 7610 patients qualified for inclusion, and these pa-
tients were subsequently grouped as follows: (1) 5094 patients, who had not
developed POAF or any other postoperative complication (no-AF; control
group); (2) 1211 patients with isolated POAF without other complications
(AF; study group); (3) 832 patients without POAF but who had developed
other complications (no-AF/C); and (4) 473 patients, who had developed
POAF and other complications (AF/C). To mitigate any potential con-
founding effects of concurrent non–rhythm-related perioperative compli-
cations on long-term survival, the subcohort of patients without any
other perioperative complications, aside from POAF, was selected as the
principal focus of the present investigation. Time 0 was defined as the
time of discharge. In-hospital deaths were considered the same as patients
with complications and were therefore excluded from the AF and no-AF
groups. POAF was defined, as per the Society of Thoracic Surgeons Data-
base, as the occurrence of POAF or atrial flutter requiring treatment (ie,
b-blockers, calcium channel blockers, amiodarone, anticoagulation, or car-
dioversion) throughout hospitalization or at readmission within 30 days
postoperatively. Telemetry was used in 100% of the patients during
hospitalization.
Surgery
Our surgical techniques have been previously reported.17,19
Cardiopulmonary bypass (96%) and aortocoronary grafting (97%) were
used in a large majority of patients. Evidence-based critical pathways
were used and periodically updated, in compliance with emerging data
documented to optimize outcomes, improve care, or decrease resource us-
age. Treatment of POAF, if it occurred, is described in the Online Data
Supplement. All efforts were made to discharge patients in a normal sinus
rhythm. Patients discharged in rate-controlled AF were routinely dis-
charged with warfarin, unless contraindicated. The database is not
granular enough to derive the subset of patients with POAF discharged
in a non–sinus rhythm.Perioperative Medications
Aspirin and b-blocker use was consistent throughout the 1994 to 2007
study period. In all patients, b-blockers were routinely administered orally
until the morning of surgery and, in stable patients, were reinstituted on
postoperative day 1. Accordingly, the point of b-blocker withdrawal (if
any) was minimized in the present series of patients. An angiotensin-
converting enzyme inhibitor was used routinely in patients with normal
renal function, including those who had been taking 1 preoperatively,
who had a history of congestive heart failure, or who had a low ejection
fraction (<35%), if hemodynamically tolerated (systolic blood pressure
>100 mm Hg) in the early phases of the study period and routinely in
the later phase of the study period in compliance with the practice guide-
lines. Aspirin (325 mg by way of a nasogastric tube) was always given
to patients on arrival at the cardiovascular intensive care unit and was
decreased to 162 mg orally daily on postoperative day 1. Amiodarone
(intravenous or orally), once approved for clinical use, was routinely
used after the onset of AF, including intraoperatively. Starting in July
1999, prophylactic amiodarone was used routinely in all patients (200
mg daily by mouth started on postoperative day 1). Before the availability
of amiodarone, quinidine and/or procainamide, in conjunction with cal-
cium channel antagonists, were used to treat POAF.
Follow-up
All-causemortality was secured from the cardiothoracic surgery follow-
up data and verified from scheduled searches of the US Social Security
Death Index database (available at: http://ssdi.genealogy.rootsweb.com),
last performed in November 2011. The follow-up period was 56 (mini-
mum) to 214 (maximum) months.diovascular Surgery c Volume 148, Number 5 1861
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The AF and no-AF groups exhibited significant demographic and risk
factor differences (Table 1 and Table E1). Such differences confounded
the outcome comparisons in observational comparison groups. To mini-
mize such confounding, we used propensity score matching to derive de-
mographic-, risk factor-, and operation-matched subcohorts of equal size.
The propensity score, or equivalently the probability that a given patient
would develop POAF, was derived by a nonparsimonious logistic multivar-
iate regression model that considered POAF status (AF or no-AF) as the
dependent outcome variable. A total of 55 preoperative risk factors
(Tables 1 and E1), demographic data, and operative variables were
entered into the model, irrespective of significance. The completeness of
revascularization index (number of grafts minus the amount of vessel
disease) was derived from the difference between the number of grafts
(number of grafts or distal anastomoses in the case of sequential grafts)
and coronary vessel disease. The year of surgery was entered as a
continuous year of series variable (1994 ¼ 1; 2007 ¼14) to account for
potential variance in reporting POAF or its treatment. Highly redundant
variables were avoided. The resulting propensity scores were distinctly
different for isolated AF versus no-AF patients (mean  SD, 0.259 
0.124 vs 0.176  0.106, respectively; P<.001). The corresponding C-sta-
tistic value was 0.703 0.008, indicating moderately good discrimination.
Next, a custom-made computer algorithm was used to obtain propensity
matched pairs. Given the abundance of no-AF patients, we considered
1-to-1 (single match), 1-to-2 (double match), and 1-to-3 (triple match)
matched pairings. The AF patients were always matched to the closest
available no-AF counterpart (1%). The adequacy of matching was
assessed using the standardized difference [d(%)].28
Statistical Analysis
Continuous and categorical data are expressed as the mean  standard
deviation or frequencies and percentages, respectively. Univariate compar-
isons before matching were performed using the chi-square, unpaired t test,
and Mann-Whitney rank test, as appropriate. Unadjusted and matched sur-
vival comparisons were done using Kaplan-Meier analysis (log-rank). The
ratios of the cumulative death hazard as a function of time were calculated
after time imputation of the calculated hazard functions. Given the
observed nonproportional hazards, the AF effect was quantified in 2
ways: (1) time-segmented hazard ratios (HRs) and 95% confidence inter-
vals (CIs) using Cox regression analysis, and (2) time-averaged HRs
derived from the calculated ratio of the cumulative death hazard functions.
Analyses were performed using the Statistical Package for Social Sciences,
version 21.0, software (IBM Corp, Armonk, NY).RESULTS
All Patients
One or more postoperative complications were docu-
mented in 2516 of 7610 CABG patients (33.1%), including
POAF in 1684 patients (22.12%). Of the latter, 1211 patients
with isolated POAF (15.9%) formed the AF group. The
no-AF control group included the remaining complication-
free patients (n ¼ 5094 [66.9%]). The incidence of POAF
in patients experiencing nonarrhythmic complications other
than isolated POAF was 36.2% (473 of 1305) compared
with the 22.2% incidence of POAF in the entire CABG
cohort. The incidence of POAF in the no-complication
cohort was 19.2% (1211 of 6305). The patients with
POAF accounted for 66.9% of all patients with any postop-
erative complication. The documented incidence of POAF
increased from 13% (1994) to around 28% (2006-2007).1862 The Journal of Thoracic and Cardiovascular SurThe patients with AF were generally older, with a larger
body habitus, had more comorbidities, required more blood
transfusions, and had a different coronary grafting profile
(Table 1). They also had a greater use of preoperative
b-blockers, digitalis, and diuretic medication. POAF was
independently predicted by older age, a large body surface
area, peripheral vascular disease, a history of cerebrovascu-
lar accident, chronic lung disease, reoperation, and preoper-
ative intra-aortic balloon pump use (Table E2). Off-pump
surgery decreased the risk of POAF.
The patients were followed up for an average of 9.7 4.2
years, and the unadjusted 18-year survival was significantly
worse in those with AF, whether accompanied by complica-
tions or not (Figure 1).
Matched Patients
Propensity score matching yielded 1196 AF/no-AF pairs
(single-match) that were well-matched with relatively
small, nonsignificant percentage of differences for all fac-
tors (Table 1). The cumulative mortality was worse for
the AF group than for the no-AF group (Figure 2). The cor-
responding ratios of the cumulative death hazard functions
varied with time (Figure 3; single-match), and the time-
averaged HR estimates varied from 1.11 (0-1 years), 1.27
(1-6 years), to 1.28 (6-17 years; Table 2 and Figure 3).
Finally, the HRs estimated using time-segmented Cox
regression analysis (3 phases) varied similarly: 1.18
(0-1 years) to a maximum of 1.37 (1-6 years) and 1.25
(6-17 years; Table 2). The estimates of the AF effect were
consistent for the double (1:2) and triple (1:3) matched
comparisons (Figure 2 and Table 2).
DISCUSSION
The results reported in the present study support the
emerging view that POAF is a ‘‘malignant’’ process that
adversely affects long-term survival in patients undergoing
otherwise uncomplicated CABG surgery, with the postoper-
ative death HR reaching a peak within 2 years of the index
operation and gradually decreasing to unity during the next
decade and a half postoperatively. By focusing on a subco-
hort of CABG patients who had experienced no other peri-
operative complications other than POAF, any potential
confounding interplay effects between POAF and other
acute perioperative adverse events were minimized. The
pathophysiology behind our observations remains perplex-
ing and obscure.
The multiple analyses we applied indicated that isolated
POAF increases the 18-year mortality in a time-varying
fashion in patients undergoing uncomplicated CABG. The
consistency of our findings for the single-, double-, and
triple-matched comparisons indicated that our finding was
robust (Table 2) and was generally in line with the lower
to middle range of previously reported POAF effects
(Table 3).2,9,11-15 The present analysis is the first togery c November 2014
TABLE 1. Selected patient data before and after propensity matching for CABG with no complications versus CABG with isolated POAF and no
other complication*
Variable








(n ¼ 1196) Difference (%)
Continuous
Age (y) 62.5  10.6 67.6  9.6 <.001 67.6  9.5 67.5  9.5 1.0
BSA (m2) 2.02  0.24 2.04  0.25 .01 2.04  0.25 2.04  0.25 1.9
Surgery yeary 6.6  3.7 7.9  3.5 <.001 7.9  3.6 7.8  3.5 0.6
EF (%) 50  11 49  11 .006 49  11 49  11 2.8
Perfusion time (min) 79  35 80  33 .63 81  35 80  34 4.1
Grafts (n) 3.2  1 3.3  1 .02 3.3  1.0 3.3  1.0 0.6
Revascularization index 0.54  0.79 0.56  0.78 .31 0.58  0.82 0.56  0.78 1.5
Categorical (%)
Male gender 69.7 71.6 .19 70.4 71.3 2.0
Obesity .11
Mild (BMI 30-35 kg/m2) 26.3 25.3 24.6 25.2 1.4
Moderate (BMI 35-40 kg/m2) 9.8 9.2 10.7 9.1 5.3
Severe (BMI>40 kg/m2) 4.4 5.9 4.8 5.9 5.2
Smoker 67.0 63.8 .04 62.8 64.1 2.3
Diabetes 33.7 35.5 .23 36.9 35.5 3.0
Insulin dependent 11.6 10.4 .25 11.3 10.5 2.4
Renal failure 2.6 3.6 .05 3.9 3.3 3.1
Hypercholesterolemia 71.1 69.5 .29 68.5 69.5 2.2
Hypertension 80.3 84.1 .003 84.8 84.0 2.1
Chronic lung disease 18.1 21.1 .01 20.3 20.9 1.5
Peripheral vascular disease 14.2 18.7 <.001 18.6 18.6 0.2
Cerebrovascular disease 22.9 28.6 <.001 28.9 28.3 1.5
Myocardial infarction 55.2 55.2 .97 53.2 55.0 3.7
Congestive heart failure 9.2 12.6 .001 12.2 12.6 1.3
Unstable angina 32.7 31.3 .37 31.2 31.1 0.2
Arrhythmiaz 9.7 10.4 .49 10.0 10.3 0.8
Multivessel disease 95.2 96.0 .20 95.5 96.1 2.9
Left main disease 20.0 24.4 .001 24.7 24.2 0.8
PCI 20.9 21.1 .83 21.7 21.1 1.4
Coronary stent used 11.5 13.4 .07 13.0 13.3 0.9
Preoperative IABP 6.5 7.6 .19 7.7 7.3 1.6
Medication
ASA 74.3 73.7 .66 72.2 73.7 3.4
Digitalis 4.3 6.5 .001 6.6 6.4 0.8
b-Blockers 63.6 68.0 .004 66.7 67.9 2.6
Diuretics 17.0 19.9 .02 20.9 19.7 2.9
Steroids 2.2 2.7 .24 2.8 2.6 1.2
Inotropes 1.5 1.7 .65 1.3 1.5 1.7
Reoperation 4.6 6.2 .02 6.1 6.0 0.4
Isolated CABG 91.8 89.3 .005 89.4 89.2 0.5
Emergency CABG 5.6 6.6 .20 6.4 6.3 0.3
Off-pump surgery 6.2 4.6 .04 5.4 4.7 3.1
ITA used 92.7 92.3 .65 92.2 92.7 1.9
Bilateral ITA 2.8 2.1 .18 2.4 2.2 1.7
Radial artery 37.9 43.5 <.001 43.7 43.6 0.3
Intraoperative IABP 1.9 1.8 .88 1.8 1.8 0.0
Transfusion (any) 28.1 35.8 <.001 37.3 35.5 3.7
Data presented as mean standard deviation or%. CABG, Coronary artery bypass grafting; No-AF group, no POAF or any other postoperative complication; AF group, isolated
POAF without other complications; BSA, body surface area; EF, ejection fraction; BMI, body mass index; PCI, percutaneous coronary intervention; IABP, intra-aortic balloon
pump; ASA, acetylsalicylic acid; ITA, internal thoracic artery. *An expanded version of the patient data are provided in Table E1. y1994¼ 1 to 2007¼ 14. zExcluding patients with
preoperative atrial fibrillation or atrial flutter.
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FIGURE 1. Comparison of unadjusted cumulative late Kaplan-Meier survival for coronary artery bypass grafting (CABG) patients grouped according to,
left, postoperative atrial fibrillation (POAF) status and, right, then subcategorized according to the presence of other postoperative complications, including
no POAF and no complications (no-AF group; n¼ 5094), isolated POAF and no other complication (AF group, n¼ 1211), postoperative complications other
than POAF (no-AF/C group, n ¼ 832), and POAF plus other postoperative complications (AF/C group, n ¼ 473). AF, Atrial fibrillation.
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Ddescribe a time-varying magnitude of the AF-late mortality
effect (time-segmented HR [HRt]). Specifically, the HRt
peaked from 1 to 6 years after surgery (HRt, 1.37) and
then decreased; however, the HRt remained elevated 6 to
17 years after surgery (HRt, 1.25).
An important aspect of our study was that it controlled for
several limitations characterizing the previous related ana-
lyses. The effect of arterial grafting, completeness of revas-
cularization, and blood transfusion was adjusted for in our
multivariate and propensity modeling. None of the previous
POAF reports considered the known effects of arterial grafts
or the completeness of revascularization on the late out-
comes of CABG.19-22 This is particularly relevant given
that POAF is more frequent in older patients who are also
less likely to receive multiple arterial grafts and, generally,
will have had a lower number of grafts constructed.20 Simi-
larly, most previous studies did not account for the associa-
tion between the perioperative use of blood products and
worse late mortality.23-25 Also, thus far, the reported
analyses have not adequately accounted for whether the
POAF episode was or was not accompanied, preceded, or
followed by other perioperative complications that,
themselves, have important independent, or potentially1864 The Journal of Thoracic and Cardiovascular Surcumulative additive, effects on the long-term outcomes.
Not surprisingly, given the increased physiologic stress
and longer length of stay associated with non-POAF postop-
erative complications, we noted that the incidence of POAF
in patients experiencing other postoperative complications
was nearly twice the rate of isolated POAF in patients
without other complications (36.2% vs 19.2%) and greater
than the rate of POAF in the overall CABG group (36.2% vs
22.1%). Wang and colleagues29 have identified a similar
trend among medical patients whose comorbidities affect
the effects of atrial fibrillation and vice versa. Finally, and,
perhaps most significantly, we are aware of no other studies
that specifically examined the temporal relationship of the
POAF–late mortality association, the evaluation of which
could be useful in attempting to identify the mechanisms
behind POAF’s malignant effects. These limitations of the
previous analyses collectively were the impetus for the pre-
sent analysis.
Despite the increasing attempts at preventative measures
during the study period, notably, with the routine imple-
mentation of prophylactic amiodarone therapy and
b-blocker therapy, the incidence of POAF increased during
the study period from only 13% in 1994 to 28% in 2007.gery c November 2014
FIGURE 2. Top, Comparison of cumulative 18-year Kaplan-Meier mortality after uncomplicated coronary artery bypass grafting (CABG) in propensity
matched patients without postoperative atrial fibrillation (POAF; no-AF group) versus patients with isolated POAF (AF group). Left, AF versus single-match
no-AF (n¼ 1196 matched pairs; 1 AF, 1 no-AF);Middle, AF versus double-match no-AF (n¼ 993 matched triplets; 1 AF, 2 no-AF); and Right, AF versus
triple-match no-AF (n ¼ 719 matched quadruplets; 1 AF, 3 no-AF). Bars represent the standard error of the cumulative mortality. Bottom, Tabular data
represent the number of patients at risk at different measurement points. AF, Atrial fibrillation.
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vigilant capture of transient burst POAF concurrent with
more sensitive telemetry technology could ostensibly have
been responsible for such a trend. The predictors of POAF
defined in the present study have corroborated the findings
of other studies30 and included older age, larger body sur-
face area, peripheral vascular disease, history of cerebro-
vascular accident, chronic obstructive pulmonary disease,
reoperation, and the need for an intra-aortic balloon
pump. In contrast to the findings from Almassi and col-
leagues,16 we found that the off-pump CABG techniqueFIGURE 3. Ratio of AF to no-AF cumulative death hazard as a function
of time after hospital discharge. Data in parentheses are 95% confidence
intervals. HRt, Time-segmented HR; HRt(0-1), HRt at 0 to 1 years postoper-
atively; HRt(1-6), HRt at 1 to 6 years postoperatively; HRt(6-17), HRt at 6 to
17 years postoperatively; CABG, coronary artery bypass grafting.
The Journal of Thoracic and Carwas protective against POAF.We did not have routine echo-
cardiographic data available to assess whether diastolic
dysfunction was associated with POAF, a finding previously
reported by Tsang and colleagues31 in nonsurgical patients
and suggesting a possible pre-existing cardiac substrate for
POAF.
The proposed explanations for why and how POAF in-
creases long-term CABG mortality remain highly specula-
tive. It is not immediately clear why POAF, presumed to be
a short-lived, nonrecurring postoperative event, would in-
crease long-termmortality for up to or beyond 10 years after
surgery. Conceivably, POAF might be a marker for patients
at increased risk of repeated episodes of AF after discharge







0-1 y 1.18 (0.77-1.81) 1.11 (1.06-1.16)
1-6 y 1.37 (1.12-1.67) 1.27 (1.25-1.28)
6-17 y 1.25 (1.05-1.49) 1.28 (1.27-1.29)
Double matched (1:2)
0-1 y 1.14 (0.74-1.75) 1.14 (1.05-1.22)
1-6 y 1.26 (1.04-1.52) 1.21 (1.20-1.23)
6-17 y 1.16 (0.98-1.36) 1.18 (1.17-1.18)
Triple matched (1:3)
0-1 y 1.04 (0.61-1.78) 1.25 (1.17-1.32)
1-6 y 1.28 (1.02-1.59) 1.17 (1.15-1.19)
6-17 y 1.31 (1.11-1.55) 1.27 (1.26-1.27)
Data presented as cumulative hazard ratios, with 95% confidence intervals in paren-
theses. *Non–model-based, estimated from the actual ratio of the cumulative hazard
functions derived from the matched AF and no-AF subcohorts.
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TABLE 3. Comparative summary of available published studies reporting on late effects of POAF in CABG patients







of death HR (95% CI) Graft no. CRI XFN
Villareal et al,11 2004 6475 994 (15.4) Included 4 No 3.40 (1.58-7.45) CR Yes No No
Villareal et al,11 2004 390 195 (100) Included 4 No 1.50 (1.26-1.77) CM/CR Yes No No
Mariscalco et al,2 2008 1832 570 (31.1) Included 7 Yes 2.13 (1.45-3.15) sPQ/CR No No Yes
Ahlsson et al,12 2009 1419 419 (29.5) Included 10 Yes 1.56 (1.23-1.98) CR No No No
Mariscalco et al,9 2009 7621 1745 (22.9) Included 13.4 No 1.22 (1.08-1.37) CR No No Yes
Filardo et al,13 2009 6899 1814 (26) Included 10 No 1.29 (1.16-1.45) PA No No No
El-Chami et al,14 2010 16,169 2985 (18.5) Included 12.5 No 1.21 (1.11-1.32) CR No No No
Attaran et al,15 2011 17,379 4984 (28.7) Included 10 No 1.29* PM No No No
Present study 6305 1211 (19.5) Excluded 18 No Data listed in Table 2 PM Yes Yes Yes
Data in parentheses are percentages, unless otherwise noted. POAF, Postoperative atrial fibrillation; HR, hazard ratio; CI, confidence interval; CRI, completeness of revascular-
ization index; XFN, transfusion of any blood products; CR, Cox regression analysis; CM, case matched; sPQ, stratified propensity score (in quintiles); PA, propensity adjusted;
PM, propensity matching. *Adjusted 10-year mortality ratio.
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appealing, given the high rate of AF progression in medical
patients along the spectrum from paroxysmal to persistent
to long-standing persistent AF,32 such a relationship has
not been defined in cardiac surgical patients and could be
a fruitful area for additional studies. Alternatively, POAF
might reflect a subclinical, and as yet undefined, disease
process that affects the atria that then, in turn, could
adversely affect long-term survival. The finding that an
atrial electromechanical interval of>120 ms predicted the
development of POAF with 100% sensitivity and 94%
specificity suggests such an underlying structural abnormal-
ity,33 although its clinical significance remains undefined.
Finally, it is possible that POAF is simply a surrogate
marker for an unknown systemic process that decreases
long-term survival. The intriguing results of our analysis
documenting the maximal risk of POAF-associated mortal-
ity within 2 years of the index surgery suggests a permissive
effect of the perioperative perturbations in homeostasis and
whatever process might underlie POAF. Whether aggres-
sive POAF prophylaxis, its more aggressive treatment, or
its much closer follow-up during the period of greatest
risk would ameliorate its adverse effects was beyond the
scope of the present study. Our study findings have, howev-
er, added to the growing body of data supporting the adop-
tion of a more aggressive search for the underlying
pathophysiology of POAF, rather than just focusing on
more aggressive treatment options of POAF as a productive
method of reducing late mortality.
One reasonable next step would be to more closely
follow-up patients with POAF, with the goal of assessing
whether this perioperative arrhythmia leads to, or reflects,
long-term cardiac electrophysiologic abnormalities and/or
altered atrial transport properties, both of which could
conceivably lead to an increased risk of subsequent throm-
boembolic events. The increasingly simplified outpatient
rhythm monitoring capabilities has made this an attractive1866 The Journal of Thoracic and Cardiovascular Surand relatively inexpensive option, particularly in light of
the results of the Framingham study, which reported signif-
icantly greater mortality in patients affected by chronic AF
than those without AF (1 year, 18% vs 5.9%; and 10 year,
61.5% vs 30%).34 The documented adjusted risk of stroke,
which was substantially increased to 2.6- to 4.5-times
greater in patients with AF,34,35 was thought to result
from an impaired atrial to ventricular transport function,
resulting in blood stasis, with subsequent left atrial
appendage thrombus formation. The observation from El-
Chami and colleagues14 that patients developing POAF af-
ter CABG who were discharged with warfarin were found
to have a lower mortality rate supports the supposition
that the adverse effects of POAFmight be based on a throm-
boembolic phenomenon. Alternatively, reduced cardiac
output from the loss of the ‘‘atrial kick’’ inherent in AF
might lead to impaired cerebral circulation and increase
the risk of noncardioembolic stroke.36 Mariscalco and col-
leagues2 linked the increased 7-year mortality in patients
developing POAF after CABG to increased thromboem-
bolic sequelae. In that study, POAF increased the risk of
mortality two- to threefold and was associated with greater
cardiac death (by a factor of 3) and disabling embolic events
(by a factor of 4). Whether these complications are associ-
ated with a minimum threshold of arrhythmic burden, are a
function of the total time in non–sinus rhythm, or, possibly,
result from a specific number of conversions between AF
and sinus rhythm has not been defined. This could represent
yet another area for future investigations, given the
increasing sophistication of technologies available for
monitoring patients after discharge from the hospital.
Study Limitations and Strengths
Our study had a number of limitations, including its
observational retrospective nature, which could have been
associated with possible residual confounding effects of
both measured and unmeasured variables. It was also agery c November 2014
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Other limitations included that we were unable to analyze
(1) the effects of prescribed medications in patients with
AF (eg, warfarin, amiodarone, other antiarrhythmic
agents); (2) the duration and number of episodes of AF
and whether POAF was successfully cardioverted or
whether the patient was discharged in rate-controlled AF;
(3) the temporal relationship between complications and
the incidence of AF and the possibility that complications
that might have occurred after AF would probably have
led to an underestimation of the true effect of AF on subse-
quent mortality, because such cases were excluded from our
study; (4) the postdischarge incidence or persistence of AF;
and (5) the effect of the evolving and changing treatment
modalities of POAF on late outcomes, because the exact
times of protocol-driven perioperative management
changes were not available to us. Our database was not suf-
ficiently granular to allow us to account for functional
completeness of revascularization, which requires informa-
tion on all areas of ischemia. Our applied approach might
not be optimal for cases such as sequential grafting or multi-
grafts to same territory. Most importantly, perhaps, the
cause-of-late-death data were also not routinely available
to further elucidate the specific mechanism underpinning
the association of POAF and increased late mortality.
CONCLUSIONS
Our results support the contention that postoperative iso-
lated POAF in uncomplicatedCABGpatients is not a benign
postoperative event but, rather, is associated with a time-
varying increased risk of late mortality, peaking at 1 to 6
years and decreasing afterward but remaining elevated for
the AF cohort during 18 years of follow-up. This effect
was found even when the potential confounding effects of
the interplay between POAF and other postoperative com-
plications were effectively eliminated. Although the signif-
icant associated mortality might seem relatively modest in
magnitude, its effect on loss of life years was large, given
the high incidence of POAF (20%-40%) after CABG.
Accordingly, we recommendmore rigorous follow-up of pa-
tients who experience POAF above and beyond the current
levels, focusing on the potential development of electro-
physiologic or atrioventricular transport function abnormal-
ities as potential fruitful research areas aimed at elucidating
the specific etiologic role of POAF on long-term survival.
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ARIAL FIBRILLATION MANAGEMENT
Prophylaxis
With the emergence of data supporting amiodarone as post-
operative atrial fibrillation (POAF) prophylaxis in the latter
half of the 1990s, all our patients were routinely treated with
amiodarone starting on postoperative day 1 and continued
for 8 weeks postoperatively, unless the patient had contrain-
dications. The usual dose was 200 mg orally, twice daily.
b-Blockers were routinely prescribed postoperatively
and were continued indefinitely. In patients with brady-
cardia, amiodarone was withheld preferentially over
b-blockers.
Atrial Fibrillation Treatment
Before 1997, POAF was treated with a combination
of calcium channel antagonists and dioxin for rate
control and procainamide for rhythm conversion.
Hemodynamically unstable POAF was treated with direct
current electrical cardioversion.
After 1997, POAF was treated with intravenous amiodar-
one for acute rate and rhythm control and was transitioned
to oral dosing after conversion to sinus rhythm. Oral amio-
darone was continued for 8 weeks postoperatively. In the
few patients with persistent rapid POAF despite intravenous
amiodarone, a intravenous diltiazem was added for rate
control. This regimen resulted in fewer than 5% of patients
with POAF being discharged from the hospital in a nonsinus
rhythm. Direct current electrical cardioversion for rhythm
control was used very rarely. Warfarin therapy was insti-
tuted only for those patients who remained in POAF for at
least several days or who continued to document multiple
sustained bursts of POAF despite maximally aggressive
pharmacologic treatment. If sinus rhythm was restored after
hospital discharge, warfarin was discontinued at 8 weeks
postoperatively.
TABLE E1. Additional patient data complementing the data in Table 1 representing demographic, comorbidity, and operative data before and
after propensity matching for CABG without complications versus CABG with isolated POAF and no other complications
Variable








(n ¼ 1196) Difference (%)
BMI (kg/m2) 29.5  5.4 29.6  5.7 .43 29.6  5.7 29.6  5.7 0.9
Coronary vessel disease (1,2,3) 2.68  0.56 2.74  0.52 .002 2.7  0.5 2.7  0.5 0.5
Crossclamp time (min) 48  23 50  23 .01 49  23 50  23 2.6
Graft no. 3.2  1 3.3  1 .02 3.3  1.0 3.3  1.0 0.6
Vein 1.8  1 1.8  1 .51 1.8  1.0 1.8  1.0 0.4
Arterial 1.45  0.78 1.51  0.79 .03 1.5  0.8 1.5  0.8 1.2
ITA 1  0.4 1.0  0.4 .36 1.0  0.4 1.0  0.3 1.5
Radial artery 0.5  0.7 0.5  0.7 .004 0.6  0.7 0.5  0.7 2.3
Categorical (%)
Current smoker 25.8 20.4 <.001 17.6 20.4 7.3
Family history of CAD 67.8 64.8 .05 65.9 65.1 1.8
Cardiogenic shock 0.60 1 .12 0.7 0.8 1.0
Preoperative IABP 6.5 7.6 .19 7.7 7.3 1.6
CABG plus 8.2 10.8 .004 10.6 10.9 0.8
Elective CABG 35.4 36.0 .68 37.1 36.3 1.7
Cardioplegia 93.4 95.0 .04 94.1 95.0 3.7
Single ITA 89.8 90.2 .74 89.8 90.6 2.5
Radial artery 37.9 43.5 <.001 43.7 43.6 0.3
Single radial artery 34.3 40.0 <.001 39.7 40.0 0.6
ITA only 3.5 3.3 .69 3.5 3.3 1.1
No ITA 7.3 7.7 .65 7.8 7.3 1.9
Vein used 87.8 89.3 .15 88.5 89.3 2.4
All arterial 12.2 10.7 .15 11.5 10.7 2.4
Radial artery and vein 29.3 36.2 <.001 35.8 36.1 0.7
Data presented as mean standard deviation or%. CABG, Coronary artery bypass grafting; No-AF group, no POAF or any other postoperative complication; AF group, isolated
POAF without other complications; BMI, body mass index; ITA, internal thoracic artery; CAD, coronary artery disease; IABP, intra-aortic balloon pump.
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TABLE E2. Multivariate logistic regression analysis results showing
predictors of postoperative atrial fibrillation among CABG patients
Predictors of POAF OR (95% CI) P value
Year* 1.102 (1.082-1.123) <.001
Age (y) 1.061 (1.053-1.069) <.001
Body surface area (m2) 3.078 (2.314-4.096) <.001
Peripheral vascular disease 1.202 (1.009-1.433) .04
Cerebrovascular accident 1.438 (1.146-1.805) .002
Chronic lung disease 1.226 (1.040-1.446) .020
Reoperation 1.376 (1.042-1.818) .030
Preoperative IABP 1.348 (1.048-1.733) .02
Off-pump surgery 0.65 (0.48-0.88) .005
POAF, Postoperative atrial fibrillation; OR, odds ratio; CI, confidence interval; IABP,
intra-aortic balloon pump. *1994 ¼ 1 to 2007 ¼ 14.
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